Microenvironment-Mediated Resistance to Anti-Androgen Therapy

Jacob J Orme; Haojie Huang

doi:10.1016/j.ccell.2020.07.007

Microenvironment-Mediated Resistance to Anti-Androgen Therapy

Cancer Cell. 2020 Aug 10;38(2):155-157. doi: 10.1016/j.ccell.2020.07.007.

Authors

Jacob J Orme¹, Haojie Huang²

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; Mayo Clinic Cancer Center, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
² Mayo Clinic Cancer Center, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; Department of Urology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. Electronic address: huang.haojie@mayo.edu.

PMID: 32781041
DOI: 10.1016/j.ccell.2020.07.007

Abstract

In this issue of Cancer Cell, Zhang et al. expose new possibilities for targeting castration-resistant prostate cancer (CRPC). Activation of the HER2/HER3 axis by cancer-associated fibroblast-secreted NRG1 mediates castration resistance, recommending novel applications of clinical anti-NRG1/HER3 therapeutics in treating CRPC.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Androgen Antagonists* / therapeutic use
Humans
Male
Neuregulin-1
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Receptors, Androgen / genetics
Tumor Microenvironment

Substances

Androgen Antagonists
NRG1 protein, human
Neuregulin-1
Receptors, Androgen